絞り込み

16555

広告

J-Startupをはじめとするベンチャー企業の入札機会を拡大します

経済産業省は、関係府省庁と連携して、政府調達に関する統一基準を改訂しました。これにより、あらゆる規模の政府調達に対してJ-Startup企業の入札が可能となりま...

  1. FB、副社長に英の元副首相 規制強化のE...
  2. 選手は1型糖尿病 日本の患者励まし参戦 ...
  3. 日欧の水星探査機、打ち上げ成功…25年に...
  4. いつになったら我々は地球工学しか方法はな...

ニュース一覧

Diabetes and Ramadan: A concise and practical update.

著者 Ahmed MH , Husain NE , Elmadhoun WM , Noor SK , Khalil AA , Almobarak AO
J Family Med Prim Care.2017 Jan-Mar ; 6(1):11-18.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (71view , 0users)

Full Text Sources

Despite the fact that the month of Ramadan includes 29-30 days and the duration of fasting for each day can last for between 12 and 16 h, it was estimated that a large number of individuals with diabetes do fast during Ramadan. In light of recent advancement of new pharmacological agents, drugs such as vildagliptin, sitagliptin, and liraglutide were found to be safe to use during this month of fasting. These therapeutic agents can also be used in combination with metformin. The use of sulfonylureas, in most of the recent guidelines about diabetes and Ramadan, seems not to gain much support due to the risk of hypoglycemia. In this review, we also addressed the use of insulin injection, insulin pump, and education before, during, and after Ramadan. Further research is needed to determine (i) the therapeutic benefit of new antidiabetic agents and (ii) the benefit of new technologies for the treatment of diabetes.
PMID: 29026740 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード